VCNX Stock Summary and Trading Ideas (Vaccinex | NASDAQ:VCNX)

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex trades on the NASDAQ stock market under the symbol VCNX.

As of April 19, 2024, VCNX stock price climbed to $4.99 with 6,894 million shares trading.

VCNX has a beta of 0.54, meaning it tends to be less sensitive to market movements. VCNX has a correlation of 0.00 to the broad based SPY ETF.

VCNX has a market cap of $7.91 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VCNX stock traded as high as $688.79 and as low as $4.43.

The top ETF exchange traded funds that VCNX belongs to (by Net Assets): VXF.

VCNX has underperformed the market in the last year with a price return of -94.6% while the SPY ETF gained +21.4%. VCNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.2% and -26.7%, respectively, while the SPY returned +4.5% and -3.3%, respectively.

VCNX support price is $4.42 and resistance is $5.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VCNX stock will trade within this expected range on the day.